Seoul Invites the World to Dream Bigger and Demand Better Cities at Asia’s Biggest Architecture Festival
24.9.2025 15:00:00 CEST | Business Wire | Press Release
The 5th Seoul Biennale of Architecture and Urbanism (SBAU) will be held from September 26 to November 18 at venues including Songhyeon Green Plaza and the Seoul Hall of Urbanism & Architecture. Over 54 days, Asia’s largest public architecture festival event will invite millions of citizens and global visitors to reimagine how cities can become “Radically More Human”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250924181590/en/
The 5th Seoul Biennale of Architecture and Urbanism Official Poster (Photo: The 5th Seoul Biennale of Architecture and Urbanism)
Curated by Thomas Heatherwick, the Seoul Biennale centers on the “Humanise Wall”—a 90-meter-long, four-story installation of 1,428 steel tiles inscribed with insights from citizens, scientists, and designers. Featuring 400 projects from 38 countries by 110 architects, the Wall acts as a manifesto for joyful, human-centered buildings. Alongside, 24 ‘Walls of Public Life’—fragments of building facades created by global designers ranging from architects to chefs and fashion designers—demonstrate how building exteriors can shape urban life.
Heatherwick, General Director of this year’s Seoul Biennale, commented, “In a world where people feel stressed and divided, we need buildings that bring us together. Seoul is boldly demanding cities that are generous, full of character, and built to last.”
The Seoul Biennale opens with the ‘Emotional City’ Forum, gathering 400 experts to debate how architecture impacts public health, while also premiering new research from the Humanise Campaign. The program includes performances by choreographer Jinyeob Cha and a special appearance from Emmy-winning actor Lee Jung-jae.
The main exhibitions include Grassroots Seoul, which reflects the feelings and visions of 500 citizens about the city’s architecture; ‘Emotionally Yours, Seoul’, a participatory digital artwork where people worldwide share photos and emotions inspired by building facades; “The City’s Face”, showcasing projects from 20 cities that explore the potential of human-centered architecture; and “From a Bird’s Eye to the Human Eye”, presenting 18 new buildings and spaces that will shape the future of Seoul.
Chang Su Lim, Director General of Future Urban Spaces Planning Bureau, Seoul Metropolitan Government, noted, “The Seoul Biennale makes the city more attractive and livable through citizens’ participation.”
All programs are free and open to the public with registration via www.yeyak.seoul.go.kr. More details at www.seoulbiennale.org and Instagram @seoulbiennale.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250924181590/en/
Contacts
PR House for the 5th Seoul Biennale of Architecture and Urbanism
Ben Kim
+82-70-8858-0778
ben.kim@pr-house.co.kr
prh1@pr-house.co.kr
prh3@pr-house.co.kr
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom